Zevorcabtagene Autoleucel Injection Application Scope

Zevorcabtagene Autoleucel Injection (zevor-cel), marketed as Sai-Kai-Ze, is an autologous B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy developed by CARsgen Therapeutics.

It is designed for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

zevorcabtagene autoleucel injection

Zevorcabtagene Autoleucel Injection Characteristics:

Ingredients: Zevorcabtagene autoleucel injection comprises autologous T cells genetically modified to express a CAR targeting BCMA. The CAR construct includes a fully human BCMA-specific single-chain variable fragment (scFv), a CD8α hinge region, a CD8α transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3ζ activation domain.
Properties: The fully human scFv design aims to reduce immunogenicity and enhance stability, potentially lowering the risk of CAR-T cell auto-activation in the absence of the tumor-associated target.
Specification: Zevorcabtagene autoleucel is supplied as a suspension for intravenous infusion.
Packaging Specification: Specific packaging details are provided in the official prescribing information.
Storage: Storage conditions are specified in the prescribing information.
Expiry Date: The shelf life is indicated on the product packaging.
Executive Standard: Zevorcabtagene autoleucel meets the standards set by the National Medical Products Administration (NMPA) of China.
Approval Number: The approval number is available in the official documentation.
Date of Revision: The date of the latest revision is noted in the prescribing information.
Manufacturer: CARsgen Therapeutics.

Guidelines for the Use of Zevorcabtagene Autoleucel Injection

Dosage and Administration: Patients should undergo lymphodepletion 2–5 days before the zevorcabtagene autoleucel infusion and receive antipyretic, analgesic, and antiallergic medications half an hour before the infusion.
Adverse Reactions: The prescribing information carries a warning regarding the risk of cytokine release syndrome (CRS) and nervous system toxicity with zevorcabtagene autoleucel.
Contraindications: Contraindications are specified in the official prescribing information.
Precautions: Precautions, including monitoring requirements and management of specific adverse reactions, are detailed in the prescribing information.

Zevorcabtagene Autoleucel Interactions

Drug Interactions: Information on potential drug interactions is provided in the prescribing information.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.